CRISPR Therapeutics AG
Stock Details
Is it expensive?
Trailing P/E Ratio
-8.47
Forward P/E Ratio
-13.09
PEG Ratio
-0.04
-6.37
Price-to-Sales (TTM)
1.50K
2.74
20.04
Market Cap
5.26B
3.49B
Is it profitable?
Net Profit Margin (TTM)
0.00%
Gross Profit Margin
0.00%
Diluted EPS (TTM)
-6.47
-30.18%
3.51M
Is it growing?
-97.60%
-100.00%
Is it risky?
1.79
10.76
13.32
206.75M
Who owns it?
73.27%
4.88%
25.34%
95.89M
95.55M
Does it pay?
0.00%
0.00%
--
--
How much cash?
1.98B
-345.01M
-205.62M
20.59
- Price
- 56.76
- Percent Change
- -0.10 (0.18%)
- Previous Close
- 56.86
- Open
- 57.81
- Low
- 55.82
- High
- 59.38
52-Week Range Position (52WRP)
Fairly Priced
Fairly Priced
within its 1-year price range
$56.76
From 52W Low
+71.84%
From 52W High
-27.68%
Today
-0.18%
1Y Change
+50.24%
6M
$68.43
3M
$53.51
1M
$48.42
Today
$56.76
From 52W Low
+71.84%
From 52W High
-27.68%
Today
-0.18%
1Y Change
+50.24%
6M
$68.43
3M
$53.51
1M
$48.42
Today
$56.76
Fairly Priced
within its 1-year price range
$56.76
Multi-Timeframe Analysis (MTA)
Uptrend
Most timeframes point up. One conflicting period introduces some uncertainty, but the overall direction is positive. Weaker than a Strong Uptrend, but still a bullish signal. As reflected in the Multi-Timeframe Analysis (MTA) below.
1M
+17.2%
3M
+6.1%
6M
-17.1%
1Y
+50.2%
Rate of Change (ROC)
Accelerating
Price is rising 15.7x faster than usual. As reflected in the ROC Momentum below, which compares recent monthly gain vs its 12-month average pace.
Relative Volume (RVOL)
Low Volume
Very little activity today. Thin trading can exaggerate price moves in either direction. As reflected in the Relative Volume (RVOL) below.
- Name
- CRISPR Therapeutics AG
- Founded
- Jan 1, 2013
- Founders
- Rodger Novak, Shaun Foy, Emmanuelle Charpentier
- CEO
- Samarth Kulkarni
- Employees
- 393
- Fiscal Year End
- Dec 31, 2024
- Address
Baarerstrasse 14
Zug
6300
Switzerland
- GICS Classification
- Health Care›Pharmaceuticals, Biotechnology & Life Sciences›Biotechnology
- Website
- www.crisprtx.com
Indicators
Operating Cash Flow
-345.01M
Net Income
-581.60M
Mixed Signal
0.59
Cash flow is meaningfully below reported profit. Some gap is normal, but a persistent gap warrants questioning of the accounting.
Most investors only look at net income, which companies can manipulate through accounting rules. Cash flow is harder to fake. A ratio above 1.0 means every dollar of profit is backed by real cash.
Indicators
Operating Cash Flow
-345.01M
Net Income
-581.60M
Mixed Signal
0.59
Cash flow is meaningfully below reported profit. Some gap is normal, but a persistent gap warrants questioning of the accounting.
Most investors only look at net income, which companies can manipulate through accounting rules. Cash flow is harder to fake. A ratio above 1.0 means every dollar of profit is backed by real cash.
Stock Details
Is it expensive?
Trailing P/E Ratio
-8.47
Forward P/E Ratio
-13.09
PEG Ratio
-0.04
-6.37
Price-to-Sales (TTM)
1.50K
2.74
20.04
Market Cap
5.26B
3.49B
Is it profitable?
Net Profit Margin (TTM)
0.00%
Gross Profit Margin
0.00%
Diluted EPS (TTM)
-6.47
-30.18%
3.51M
Is it growing?
-97.60%
-100.00%
Is it risky?
1.79
10.76
13.32
206.75M
Who owns it?
73.27%
4.88%
25.34%
95.89M
95.55M
Does it pay?
0.00%
0.00%
--
--
How much cash?
1.98B
-345.01M
-205.62M
20.59
- Price
- 56.76
- Percent Change
- -0.10 (0.18%)
- Previous Close
- 56.86
- Open
- 57.81
- Low
- 55.82
- High
- 59.38
52-Week Range Position (52WRP)
Fairly Priced
Fairly Priced
within its 1-year price range
$56.76
From 52W Low
+71.84%
From 52W High
-27.68%
Today
-0.18%
1Y Change
+50.24%
6M
$68.43
3M
$53.51
1M
$48.42
Today
$56.76
From 52W Low
+71.84%
From 52W High
-27.68%
Today
-0.18%
1Y Change
+50.24%
6M
$68.43
3M
$53.51
1M
$48.42
Today
$56.76
Fairly Priced
within its 1-year price range
$56.76
Multi-Timeframe Analysis (MTA)
Uptrend
Most timeframes point up. One conflicting period introduces some uncertainty, but the overall direction is positive. Weaker than a Strong Uptrend, but still a bullish signal. As reflected in the Multi-Timeframe Analysis (MTA) below.
1M
+17.2%
3M
+6.1%
6M
-17.1%
1Y
+50.2%
Rate of Change (ROC)
Accelerating
Price is rising 15.7x faster than usual. As reflected in the ROC Momentum below, which compares recent monthly gain vs its 12-month average pace.
Relative Volume (RVOL)
Low Volume
Very little activity today. Thin trading can exaggerate price moves in either direction. As reflected in the Relative Volume (RVOL) below.
- Name
- CRISPR Therapeutics AG
- Founded
- Jan 1, 2013
- Founders
- Rodger Novak, Shaun Foy, Emmanuelle Charpentier
- CEO
- Samarth Kulkarni
- Employees
- 393
- Fiscal Year End
- Dec 31, 2024
- Address
Baarerstrasse 14
Zug
6300
Switzerland
- GICS Classification
- Health Care›Pharmaceuticals, Biotechnology & Life Sciences›Biotechnology
- Website
- www.crisprtx.com